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searched by using PubMed.gov with key words of Validation Health Economics 
Cancer. Frequencies are tabulated by validation criterion and publication year. Statisti-
cal methods employed for testing each validation criteria are summarized. RESULTS: 
Sixty-seven articles are found. 31 articles reveal validation effort. Criteria frequently 
tested for validation are external validity, internal validity, face validity, criterion 
validity, content validity, predictive, reliability, responsiveness, sensitivity. Sixty-eight 
percent of articles were published since 2003 and 89% since 2000. For testing validity 
of research model, correlation, regression, mean are statistics employed frequently. 
For testing validity of data, sensitivity & speciﬁcity, and positive predictive value are 
statistics used. CONCLUSIONS: Validation effort may have increased since 2003 
when guidelines from regulatory agencies have been published. But most articles’ vali-
dations were partially done. Few articles followed the guidelines to the full extent. In 
contrast to validation of quality of life instruments, validation of health economics 
outcomes models lacks theoretical foundation. It is recommended to follow guidelines 
to enhance credibility of the health outcomes research.
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OBJECTIVES: to estimate medical, social and economic effectiveness of treatment of 
children with the Non-Hodgkin lymphomas (NHLs) according to the NHL-BFM-95 
protocol. METHODS: The study included 62 children with NHL, 50 of them with 
B-cell lymphomas, and 12 with T-cell lymphomas. All children received treatment 
according to the NHL-BFM-95 protocol. Eighteen children, 12 boys and 6 girls, 
entered a study group aimed at estimating gained years of quality-adjusted life years. 
As of January 1st, 2010 the follow-up period comprised 13 years. Survival rates were 
estimated using the Kaplan–Meier method. RESULTS: A 5-year event-free survival of 
patients treated according to the NHL-BFM-95 protocol for patients with B-cell and 
T-cell lymphomas was 0,81 ± 0,08 and 0,54 ± 0,14 respectively. Chemotherapy 
complications appear to be the main reason for mortality during program treatment 
which is a rate of controlled mortality correlating with the quality of the accompany-
ing treatment. The assumed number of quality-adjusted life years were estimated for 
each of the patients considering the known disease outcome. A total of 657 years of 
quality-adjusted life years were saved for 18 patients with NHL treated according to 
the NHL-BFM-95 protocol; therefore the average rate is 36,5 years. This rate could 
be used for cost-effectiveness analysis of treatment as a proof of expensive treatment 
advisability for society from cost perspective. In 2009, the Republic children’s clinical 
hospital (Izhevsk) conducted a survey on clinico-economic cost of treatment of chil-
dren with NHL according to the NHL-BFM-95 protocol. The cost of one patient 
illness appeared to be US$29,550. The method of cost-effectiveness analysis on this 
medical technology with the calculation of saved years of employability and GDP 
produced during this time (US$1356 estimated) demonstrates its social effectiveness. 
CONCLUSIONS: The performed clinoco-economic analysis proves medical, social 
and economic effectiveness of treatment of children with NHL according to the NHL-
BFM-95 protocol.
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OBJECTIVES: Bendamustine and alemtuzumab are approved for treatment of chronic 
lymphocytic leukemia (CLL) in the US, and both are more expensive than chloram-
bucil. This analysis evaluated the cost-effectiveness of bendamustine (100 mg/m2/day 
intravenously, for 6 28-day cycles) vs. alemtuzumab (30 mg intravenously, for 12 
weeks) vs. chlorambucil (0.8 mg/kg/day orally, for 12 cycles) in ﬁrst-line treatment of 
CLL in the US. METHODS: The model was a discrete event simulation from a payer 
perspective, discounted at 3% annually with a lifetime horizon. Simulated patients 
were assigned baseline characteristics, treatment response, risk of adverse events, and 
infections based on data from 2 pivotal trials (Knauf et al, 2007; Knauf et al, 2009: 
bendamustine; Hillmen et al 2007: alemtuzumab) and supplemented by literature. 
Progression-free survival (PFS) and survival were predicted using survival functions 
derived from the bendamustine trial data. Resource use, costs (2009 US$), and utilities 
were from US databases and literature. RESULTS: The median PFS for bendamustine, 
alemtuzumab, and chlorambucil were 24, 15, and 11 months, respectively, and the 
total costs/patient were $75,243, $113,350, and $38,700, respectively. The incremen-
tal life years (LY) and quality-adjusted life years (QALYs) for bendamustine vs. 
chlorambucil were 0.89 and 0.72, respectively, resulting in incremental cost-effective-
ness ratio (ICER) of $50,763/QALY. Bendamustine was dominant over alemtuzumab, 
i.e., the incremental LYs and QALYs for bendamustine were 0.73 and 0.57, respec-
tively, at lower costs. Sensitivity analyses over a wide range of parameters indicated 
that bendamustine was dominant over alemtuzumab in all scenarios. The ICERs for 
bendamustine vs. chlorambucil ranged between $44,819 and $62,624/QALY. CON-
CLUSIONS: Treatment of CLL with bendamustine costs less and provides better 
health outcomes compared to alemtuzumab. Although bendamustine led to higher 
costs vs. chlorambucil, bendamustine was associated with an additional year of PFS, 
and the estimated ICER was within the acceptable, threshold commonly used in the 
US of $50,000–$100,000/QALY.
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OBJECTIVES: Prostate Cancer (PCa) disease management for intermediate-risk 
patients is challenging due to the uncertainty in risk at the time of biopsy. Novel 
prognostic tools that better estimate the risk of disease progression post-biopsy may 
save costs and improve quality of life by directing patients to more appropriate treat-
ments. We analyzed the cost of PCa management for patients stratiﬁed as intermediate-
risk by American Urological Association (AUA) guidelines. Management strategies 
were modeled according to standard care and following a new prognostic tool, Pros-
tate Px®+. The new test employs morphologic and biomarker features, in addition to 
the AUA clinical-pathologic ones, to predict PCa disease progression at biopsy. 
METHODS: A cost-minimization analysis was performed on a multi-institution 
cohort of 399 AUA intermediate-risk patients. Px+ reclassiﬁed 69% of patients as 
low-risk and 31% as high-risk. A decision analysis model was developed, accounting 
for ﬁve primary treatments (radical prostatectomy (RP), radiation therapy, primary 
hormonal therapy, brachytherapy and active surveillance) plus secondary treatments. 
Standard management for AUA intermediate-risk was compared with management 
post Px+ reclassiﬁcation. Patients reclassiﬁed as low-risk were assumed to follow low-
risk treatment distributions and disease progression; those reclassiﬁed as high-risk 
were assumed to follow high-risk treatment distributions and disease progression. The 
model was informed with costs and probabilities from the literature and analyzed 
from Medicare’s perspective with a 10 year time horizon. RESULTS: The expected 
cost per patient of standard management was $30,287 and $27,987 for Px+ (including 
the $2,968 list price), resulting in an expected cost savings of $2,300. One-way sen-
sitivity analysis conﬁrmed that modeled management post Px+ saves costs for all 
variables except for certain values of recurrence probabilities post RP in low-risk and 
intermediate-risk patients. CONCLUSIONS: Novel personalized risk assessment tools 
such as Px+ improve PCa risk stratiﬁcation, impacting disease management and 
potentially saving costs over current standards.
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OBJECTIVES: To determine, from the societal perspective, the relative cost-effective-
ness of four serotonin-type-3 receptor antagonists (5HT3-RA’s), palonosetron, ondan-
setron, granisetron, and dolasteron, for chemotherapy-induced nausea and vomiting 
(CINV) in patients with non-small cell lung cancer (NSCLC) receiving cisplatin-based 
chemotherapy. METHODS: A Markov model simulating monthly cycles was used to 
estimate lifetime costs and QALY’s gained by each of the interventions. Costs and 
utilities were discounted by 3% annually. Transition probabilities were estimated 
using clinical trial results. The study population included a hypothetical cohort with 
advanced NSCLC receiving cisplatin-based chemotherapy. In accordance with 
National Comprehensive Cancer Network guidelines, ﬁrst-line therapy for CINV 
included a 5-HT3 RA. Prochlorperazine was used for breakthrough episodes. Direct 
costs (2009 US$) included medication costs, adverse events, health care professional 
fees, hospitalizations, laboratory fees, and cancer progression costs. Indirect costs 
included the opportunity cost of medical visits. Average life expectancies were calcu-
lated from clinical trial results, adjusting for population-based life expectancies. Life 
years were weighted using utility scores elicited from the general public via a standard 
gamble technique. RESULTS: Assuming a societal cost-effectiveness threshold of 
$150,000/QALY, ondansetron and granisetron were cost-effective relative to no treat-
ment, at $103,759/QALY and $128,426/QALY, respectively. The incremental cost-
effectiveness ratio (ICER) between ondansteron and granisteron was $310,249/QALY. 
Dolasetron was dominated by ondansetron and granisetron. Palonosetron was not 
cost-effective at $799,696/QALY. In the threshold analysis, granisetron would need 
to cost $13.70/month to be cost-effective relative to ondansetron. The model was 
sensitive to changes in utility values and transition probabilities, resulting in a greater 
than 50% change in the estimated ICER. In addition, a 50–100% increase in chemo-
therapy efﬁcacy resulted in a 40–70% change in the ICER. CONCLUSIONS: For US 
patients with NSCLC on cisplatin-based chemotherapy, ondansetron is the most cost 
effective antiemetic. Generic granisetron is cost-effective relative to no antiemetics and 
at $13.70/month or less, would be cost-effective relative to ondansetron.
